Wednesday, December 11, 2013 3:26:29 PM
From todays PR:
"In contrast to previous experiments reported by the company, in this set of experiments, recipient animals possessed an intact immune system, implying that the HemaXellerate I™ product does not trigger adverse immune reactions."
IMO the weakened immune system issue was the major concern FDA had a few months ago. Now this concern is gone!!!
BMSN is clearing its path to orphan drug status!
Go BMSN
"In contrast to previous experiments reported by the company, in this set of experiments, recipient animals possessed an intact immune system, implying that the HemaXellerate I™ product does not trigger adverse immune reactions."
IMO the weakened immune system issue was the major concern FDA had a few months ago. Now this concern is gone!!!
BMSN is clearing its path to orphan drug status!
Go BMSN
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
